{"title":"-455A Allele May Be a Protective Locus for Aseptic Lower Extremity Superficial Thrombophlebitis.","authors":"Ruixiang Luo, Shengbin Han, Jingzhe Xu, Shun Ding, Hongxi Guan","doi":"10.1089/gtmb.2024.0503","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Objective:</i></b> We designed a prospective experiment to explore the whole promoter region of fibrinogen B β (FGB) with the intent to detect all single nucleotide polymorphisms (SNPs) in this region and their impact on the susceptibility of aseptic lower extremity superficial thrombophlebitis (STP). <b><i>Methods:</i></b> The experiment was conducted prospectively and randomized. Thirty-four idiopathic STP patients and 50 healthy people were recruited, respectively, as case and control groups. The whole FGB promoter was gene sequenced. <b><i>Results:</i></b> From upstream to downstream of the promoter, a totally 6 SNPs-rs1800789 (-1420G/A), rs2227389 (-993C/T), rs1800791 (-854G/A), rs1800790 (-455G/A), rs1800788 (-249C/T), and rs1800787 (-148C/T) were detected via gene sequencing. A statistical difference was found in the -455A allele (rs1800790) between the two groups (<i>p</i> < 0.05, odds ratio = 0.368, 95% confidence interval: 0.093 - 0.852), while no statistical difference as for the other five SNPs (all <i>p</i> > 0.05). <b><i>Conclusions:</i></b> The 455A allele may be a protective locus for the onset of STP. However, due to the low incidence of idiopathic STP, multiple verification tests are still needed.</p>","PeriodicalId":12603,"journal":{"name":"Genetic testing and molecular biomarkers","volume":" ","pages":"144-151"},"PeriodicalIF":1.1000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genetic testing and molecular biomarkers","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1089/gtmb.2024.0503","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/21 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: We designed a prospective experiment to explore the whole promoter region of fibrinogen B β (FGB) with the intent to detect all single nucleotide polymorphisms (SNPs) in this region and their impact on the susceptibility of aseptic lower extremity superficial thrombophlebitis (STP). Methods: The experiment was conducted prospectively and randomized. Thirty-four idiopathic STP patients and 50 healthy people were recruited, respectively, as case and control groups. The whole FGB promoter was gene sequenced. Results: From upstream to downstream of the promoter, a totally 6 SNPs-rs1800789 (-1420G/A), rs2227389 (-993C/T), rs1800791 (-854G/A), rs1800790 (-455G/A), rs1800788 (-249C/T), and rs1800787 (-148C/T) were detected via gene sequencing. A statistical difference was found in the -455A allele (rs1800790) between the two groups (p < 0.05, odds ratio = 0.368, 95% confidence interval: 0.093 - 0.852), while no statistical difference as for the other five SNPs (all p > 0.05). Conclusions: The 455A allele may be a protective locus for the onset of STP. However, due to the low incidence of idiopathic STP, multiple verification tests are still needed.
期刊介绍:
Genetic Testing and Molecular Biomarkers is the leading peer-reviewed journal covering all aspects of human genetic testing including molecular biomarkers. The Journal provides a forum for the development of new technology; the application of testing to decision making in an increasingly varied set of clinical situations; ethical, legal, social, and economic aspects of genetic testing; and issues concerning effective genetic counseling. This is the definitive resource for researchers, clinicians, and scientists who develop, perform, and interpret genetic tests and their results.
Genetic Testing and Molecular Biomarkers coverage includes:
-Diagnosis across the life span-
Risk assessment-
Carrier detection in individuals, couples, and populations-
Novel methods and new instrumentation for genetic testing-
Results of molecular, biochemical, and cytogenetic testing-
Genetic counseling